Baxter International Inc.

Baxter Healthcare Sa

Immuno Aktiengesellschaft

Baxter Vaccine Ag

Georg Holzer

Friedrich Dorner

Falko-Guenter Falkner

Falko-Gunter Falkner

Josef Mayrhofer

Sogue Coulibaly

The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.

Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods

A chimeric poxvirus is disclosed, which comprises the sequences of the vector component of a retroviral vector particle and optionally the packaging component of a defective retroviral particle. The chimeric poxvirus according to the invention particularly can be used for applications in gene therapy or tumor therapy.

Chimeric poxvirus comprising sequences of a retroviral vector component

Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus are provided for protein production and vaccination. A DNA polynucleotide encoding a protein is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.

Recombinant poxviruses with foreign DNA in essential regions

recombinant poxviruses with foreign DNA in essential regions

Growing community of inventors

Vienna, Austria

Georg Holzer